

What's New In Tick-borne Disease?

Lyme Disease

Relapsing Fever

and beyond...



Marc Roger Couturier, Ph.D., D(ABMM)

Medical Director, Infectious Disease and Immunology

ARUP Laboratories

Associate Professor of Pathology

University of Utah


Objectives

1. Understand the epidemiology of tick-borne diseases and the ticks that vector the diseases.
2. Recognize the growing list of tick-borne diseases.
3. Recall the testing available for detection of tick-borne diseases.


Anatomy of the tick...

Hard Shell Tick (Ixodid) vs Soft Shell (Agasid)

a. HARD TICK




b. SOFT TICK



<https://www.cdc.gov/dpdx/ticks/index.html>

Hard Ticks-Life Cycle



<https://www.cdc.gov/dpdx/ticks/index.html>

Ixodid Ticks – male vs. female



female



male

<https://www.cdc.gov/dpdx/ticks/index.html>

Hard Shelled Ticks of the Northeast



Ixodes scapularis
“Deer tick or black-legged tick”



Rhipicephalus sanguineus
“Brown dog tick”



Dermacentor variabilis
“American Dog Tick”




Amblyomma americanum
“Lonestar Tick”

<https://www.cdc.gov/dpdx/ticks/index.html>

Amblyomma americanum



Amblyomma americanum



- *Ehrlichia ewingii*
 - *Ehrlichia chaffeensis*
 - *Francisella tularensis*
 - STARI (Southern Tick Associated Rash Illness)
 - Heartland virus
- } Human monocytic ehrlichiosis

Rhipicephalus sanguineus



Rhipicephalus sanguineus



- *Rickettsia rickettsii* (Rocky mountain spotted fever)
In the southern USA only

Dermacentor variabilis



Dermacentor variabilis.



- *Ehrlichia* spp. (Human monocytic ehrlichiosis)
- *Rickettsia rickettsii* (Rocky mountain spotted fever)
- *Francisella tularensis* (Tularemia)

Ixodes scapularis




Ixodes scapularis



- *Borrelia burgdorferi*
- *Borrelia mayonii*
- *Borrelia miyamotoi* (Tick-borne relapsing fever-like)
- Deer tick virus (Powassan virus, lineage II)
- *Babesia spp.*
- *Anaplasma phagocytophilum*
(Human granulocytic Anaplasmosis)

Easiest way to identify




Smaller than you may expect



<https://www.cdc.gov/lyme/resources/tickbornediseases.pdf>

Smaller than you may expect



<https://www.cdc.gov/lyme/transmission/index.html>

Harder to identify when “full”



<https://www.cdc.gov/dpdx/ticks/index.html>

Why are the ticks so bad this year?

A song of humans, hosts, forests, and food!



<http://www.commonweeder.com/the-harvard-forest/>



<http://www.commonweeder.com/the-harvard-forest/>




<http://www.commonweeder.com/the-harvard-forest/>


Evolution of Food – 1800s




Evolution of Food – 1900s




Evolution of Food – Late 1900s-2000s



Evolution of Food – Late 1900s-2000s





Mast Year




White-footed mouse





<http://www.npr.org/sections/goatsandsoda/2017/03/06/518219485/forbidding-forecast-for-lyme-disease-in-the-northeast>





<http://www.npr.org/sections/goatsandsoda/2017/03/06/518219485/forbidding-forecast-for-lyme-disease-in-the-northeast>




- *Borrelia burgdorferi* (Lyme disease)
- *Borrelia mayonii* (Lyme disease)
- *Borrelia miyamotoi* (Tick-borne relapsing fever-like)
- Deer tick virus (Powassan virus, lineage II)
- *Babesia spp.*
- *Anaplasma phagocytophilum* (Human granulocytic Anaplasmosis)

Lyme Disease

Lyme disease (LD)

- *Borrelia burgdorferi* and *B. mayoni* (in N. America)
 - Gram-negative spirochete, motile by polar flagella
- Fastidious, not cultured in the clinical laboratory
- Vector
 - *Ixodes scapularis* (eastern/central)
 - *Ixodes pacificus* (west coast regions)
 - Infected Ixodes (nymph & mature adult) MUST feed >24 hours for transmission
 - @24 hours 5% of infected ticks will transmit
 - @48 hours 50% of infected ticks will transmit
 - @96 hours 100% of infected ticks will transmit



Symptoms

- Early LD or Stage 1 (3-30 days post bite)
 - Red, expanding rash called erythema migrans (EM) or “bull’s eye rash” (7-14 days)
 - Present in up to 80% of cases
 - Fatigue, chills, fever, headache, muscle and joint aches, and swollen lymph nodes
 - All cases present w/combinations of these symptoms



Symptoms

- Early disseminated LD or Stage 2 (days to weeks)
 - Additional EM lesions in other areas of the body
 - Facial or Bell's palsy
 - Severe headaches and neck stiffness due to meningitis
 - Pain and swelling in the large joints
 - Shooting pains that may interfere with sleep
 - Heart palpitations and dizziness due to changes in heartbeat
- Symptoms will resolve over weeks without treatment but can lead to serious complications

Symptoms

- Late disseminated LD or Stage 3 (months to years)
 - Can occur even after treatment for Lyme
 - Muscle & joint pain
 - Cognitive defects (“slow”)
 - Sleep disturbance
 - Fatigue


Diagnostic tests

- Shortly after bite –
 - Silver stain (not diagnostic)
 - PCR from lesion biopsy
- Second stage of disease (dissemination)
 - *Serology (may be negative due to therapy)*
 - PCR from joint fluid, lesion
 - Blood and CSF are poor samples
- Late stage of illness
 - *Serology testing only*

Case Presentation

- 21 year old male from central Nova Scotia
- Experienced outdoorsman, hiker, hunter, and fisherman
- 3 day fishing and camping weekend in Andover, Maine
 - Memorial Day, 2002
- Noted tick attached to calf (unknown duration), removed with fishing pliers, cauterized pliers and wound with whiskey
- Continued fishing and camping

Andover, ME – Population 821



Case cont.



Lovejoy Bridge, Ellis River



Case cont.

- 3 days post-camping trip developed rash on right calf



(not the actual rash)

- No other symptoms
- No physician seen (remember it is 2002)

Fast Forward


- 2012 – Now 31 year old microbiologist (and laboratory director)
- Participates in lab blood draw for QC purposes as “negative serum sample” for Lyme disease ELISA and Western blots
- + total antibody ELISA (screen)
 - Not a great negative QC point...
- Just for fun...
 - IgM blot – negative
 - IgG blot positive 7 of 10 bands
- Does this patient have Lyme disease?

No...but it is not always that easy

- 2003-2009 – Patient lived in Edmonton, Alberta Canada
 - Not a lyme endemic region
 - One vacation to lyme endemic region in 2006 & 2009
 - No observed tick bites, no rashes, no other symptoms
- 2009-2017 – Patient lived in Salt Lake City, UT
 - Not a lyme endemic region
- Patient grew up in central Maine

Case 2.

- 37 year old male from Andover, Massachusetts
- Never hikes, hates camping, generally disgusted by insects and nature
- Enjoys sitting in his back yard drinking, BBQing, and entertaining friends and family
- Enjoys golfing (2-3 rounds/week) – but he's not very good at it
- Does not recall a tick bite
- No rash
- Develops flu-like illness; body aches, headache, low grade fever



Case 2. Continued


- Patient tested for LD
- Screen: ELISA +
- Immunoblot:
 - IgM + (3 of 3 bands)
 - IgG + (6 of 10 bands)
- Is this LD?
- YES. Clear cut LD

Quiz: What activity is the highest risk for LD in New England?

1. Camping
2. Hiking
3. Golfing
4. Yard work
5. Sleeping in cabins

Current State of LD Testing

Two-Tiered Testing for Lyme Disease



National Center for Emerging and Zoonotic Infectious Diseases
Division of Vector Borne Diseases | Bacterial Diseases Branch



Screening Assays

- Classic:
 - Whole Cell Lysate antigen source ELISA
- Evolved:
 - C6 peptide ELISA (26-amino acid recombinant region of VsIE)
 - Immunetics/Oxford/Quest
 - VsIE Chemiluminescent Immunoassay (CIA)
 - Diasorin (FDA clearance 2007)
 - rVsIE1/pepC10 (OspC) ELISA
 - Zeus (FDA clearance 2013)

Screening Assay Performance

“Standard”

“Newer”

TABLE 1 Select studies that evaluated the performance characteristics of the WCS, VlsE, C6, and pepC10 immunoassays alone or in combination with supplemental Western blot testing

Assay ^a	Sensitivity (%)		Specificity (%)	
	Early (stage 1)	Late (stages 2, 3)	Healthy donors ^b	Patients with non-LD infections or conditions
WCS ELISA	74.9	97.7, 98.4	96.4	89.3
WCS ELISA + WB	35.2	77.3, 95.9	99.5	99.2
C6 ELISA	66.5	88.6, 98.4	98.8	99.5
C6 ELISA + WB	34.5	75, 95.1	99.5	99.5
VlsE CIA ^c	69.8	100	99.5	93.7
pepC10 kELISA	47.3	46.1, 10.3	100	98.0
VlsE/pepC10 kELISA	67.2	88.5, 94.1	99.2	96.7

^a WCS, whole-cell sonicate; VlsE, variable major protein (Vmp)-like sequence, expressed; WB, Western blot; ELISA, enzyme linked immunosorbent assay; CIA, chemiluminescent immunoassay; kELISA, kinetic ELISA.


^b Data from healthy donors from regions in which Lyme disease is endemic and from those in which it is not endemic were combined.

^c Lyme disease stages 2 and 3 were not separated out in this study.

Theel. J Clin Micro. 2016 54(5), 1191-1196.

Back to the Algorithm


Two-Tiered Testing for Lyme Disease



National Center for Emerging and Zoonotic Infectious Diseases
Division of Vector Borne Diseases | Bacterial Diseases Branch



Details on the Blots





- IgM blot: 2 of 3 conserved bands*
 - Only run on patients with suspected symptom onset <30 days
 - If positive and IgG blot is negative after 30 days = false positive
 - Blot criteria do not apply after 30 days of symptoms
- IgG blot: 5 of 10 conserved bands*
 - Difficult to interpret in patients from endemic regions with unclear history
 - Think case 1 ☺

Unchanged since 1995

CDC. Morb Mortal Weekly Rep. 1995. 44(31);590-591

Blots



Automated Immunoblotting & Densitometry

Test: Borrelia B31 ViraStripe®IgG

Strip: LGG0627178715-16

Bands:

93	66	58	45	41	39	30	28	23	18
104	118	086	122	090	081	136			

kDa


Intensity to Cut-off

Patient Strip: 16



Cut-Off Strip:

Band-Locator:



Do we really need blots?

Alternative Two-Tier algorithm

TABLE 2 Comparison of the traditional TTTA to a 2-EIA TTTA and the C6 ELISA alone in sera from patients with well-characterized Lyme disease^a

Testing algorithm	Sensitivity (%)			Specificity (%)	
	Stage 1 (n = 114)	Stage 2 (n = 26)	Stage 3 (n = 29)	Healthy donors ^b (n = 1,246)	Patients with a non-LD infection or condition (n = 54)
Traditional ^c	42.1	73.1	100	99.4	100
C6 ELISA alone	56.1	100	100	98.4	98.1
2-ELISA ^d	52.6	100	100	99.4	100

^a Adapted from reference 17.

^b Data from healthy donors from regions in which Lyme disease is endemic and from those in which it is not endemic were combined.

^c Traditional TTTA, WCS ELISA followed by Western blot analysis.

^d 2-ELISA, WCS ELISA followed by C6-ELISA.


ELISA→ELISA

↓\$ (27-44%)

**↑ Accuracy
(27%)**

Reference 17 in figure: Branda et al. 2011. Clin Infect Dis 53:541–547.

Alternative Two-Tier algorithm



- CDC's Lyme Serum Repository specimens used
 - Carefully curated – clinically well defined positives
 - Common interfering conditions for “negatives” and non-endemic volunteer negatives

Pegalajar-Jurado et al. J Clin Microbiol 2018: 56(8).

Commentary Highlight



Journal of
Clinical Microbiology



[Advanced Search](#)

[Home](#)

[Articles](#)

[For Authors](#)

[About the Journal](#)

[Subscribe](#)


Commentary

Revisiting the Lyme Disease Serodiagnostic Algorithm: the Momentum Gathers

[Adriana R. Marques](#)

Karen C. Carroll, Editor

Pegalajar-Jurado et al. J Clin Microbiol 2018: 56(8).



Interpretation uses standardized criteria: at least 2 of 3 bands for a positive IgM Western blot, and 5 of 10 bands for a positive IgG Western blot

Illness duration less or equal to 30 days

Use both IgM and IgG Western blot results

Illness duration more than 30 days

Use only IgG Western blot results




TABLE 1

Sensitivity of MTT algorithm versus that of the STT algorithm in acute-phase samples from patients with erythema migrans

Reference(s) (no.)	MTT algorithm ^a		STT algorithm ^b	
	Test program ^c	Acute-phase EM sensitivity (%)	Test program	Acute-phase EM sensitivity (%)
Branda et al. (16)	WCS Vidas f/b C6 EIA	52.6	WCS Vidas f/b WB	42.1
Branda et al. (27)	WCS W EIA f/b C6 EIA	38.2	C6 EIA f/b WB	36.4
	WCS W EIA f/b VisE CLIA	36.4	VisE CLIA f/b WB	34.5
	VisE CLIA f/b C6 EIA	54.5	WCS W f/b WB	25.4
Molins et al. (28) ^d	WCS Vidas f/b C6 EIA	50	WCS Vidas f/b WB	47.5
Molins et al. (29) ^d	WCS Vidas f/b C6 EIA	50	LYM/G Vidas f/b WB	42.5
	LYM/LYG f/b C6 EIA	55	WCS Vidas f/b WB	47.5
Pegalajar-Jurado et al. (4) ^d	WCS Captia f/b C6 EIA	55	WCS Captia f/b WB	50
	WCS Captia f/b VisE CLIA	57.5	VisE CLIA f/b WB	42.5
	VisE CLIA f/b C6 EIA	50	C6 EIA f/b WB ^e	42.5
Wormser et al. (11, 25)	WCS EIA f/b C6 EIA ^f	58.4	C6 EIA f/b WB	37.6
			WCS f/b WB	38.3

Examples of Future Areas of Investigation

- Novel/expanded antigen investigations for multiplex antibody detection
 - Bead-based detection
- Immuno-PCR (iPCR)
 - Optimize high specificity of C6 peptide with amplification of PCR
 - Reporter antibody contains DNA tag which is amplified after binding C6 specific antibodies
- Metabolomic profiling

<https://www.cdc.gov/lyme/diagnostesting/labtest/otherlab/index.html>

Metabolomic profiling

- CDC study to detect early LD with better sensitivity
- Characterize low-molecular-weight (<15kDa) molecules in patients with early LD vs absence or baseline in healthy controls
- Liquid chromatography mass spectrometry
- 44 markers for early LD mainly lipids and lipophilic molecules
- More sensitive (88%) than traditional two-tier algorithm (43%) and 2-ELISA methods (48%)
- Not ready for clinical labs & will require FDA clearance

Molins et al. 2015. Clin Infect Dis 60:1767–1775.

Examples of Unapproved Testing for Diagnosis

- Urine antigen detection
- Culture, immunofluorescence staining, or cell sorting of cell wall-deficient or cystic forms of *B. burgdorferi*
- Lymphocyte transformation tests
- Quantitative CD57 lymphocyte assays
- “Reverse Western blots”
- In-house criteria for interpretation of immunoblots
- IgM or IgG tests without a previous screening test

<https://www.cdc.gov/lyme/diagnostictesting/labtest/otherlab/index.html>

LD in Summary

- LD is a complicated infection to diagnose
 - Symptoms and exposure history can be difficult to accurately ascertain
- Emotionally and politically charged
- Technological advancements have been slow to materialize
 - New avenues of testing show promise but require more clinical validation

Case of the Chills

- 56 yo male returned from fishing vacation in southeastern California mountains 7 days prior to symptom onset
 - Stayed in upscale resort rental cabins
 - Did not recall any insect bites, no documented ticks seen
 - Spring 2012
- Fevers $>104^{\circ}\text{F}$, 3x over ~2 d
 - Drenching sweats followed by intense chills
 - Symptoms resolved for a week then returned
- No other recent travel history



Tick Born Relapsing Fever (TBRF) and beyond

Tick Borne Relapsing Fever (TBRF)

- Causative organism in the USA...

– *Borrelia hermsii*
– *Borrelia parkeri*
– *Borrelia turicatae* } Vector → { – *Ornithodoros hermsi*
– *Ornithodoros parkeri*
– *Ornithodoros turicata*




– ***Borrelia miyamotoi* Vector → – *Ixodes scapularis*



**TBRF genetic group, but clinically not TBRF

Approximate Geographic Distribution



B. hermsii
B. parkeri
B. turicatae
B. miyamotoi

Case Distribution





■ Each dot, placed randomly within the county of exposure (where known), represents one case.



■ Each dot, placed randomly within the county of residence, represents one case.

<https://www.cdc.gov/relapsing-fever/distribution/index.html>

Hard Shell Tick (Ixodid) vs Soft Shell (Agasid)



<https://www.cdc.gov/dpdx/ticks/index.html>

Ornithodoros spp.



*Ornithodoros
turicata*




*Ornithodoros
hermsi*



Dworkin et al. Infect Dis Clin North Am. 2008 Sep; 22(3): 449–viii


Argasidae life cycle



<https://www.cdc.gov/dpdx/ticks/index.html>

TBRF

- Recurring febrile episodes ~3 days, separated by afebrile period ~7 days



- >75%: headache, myalgia, chills, nausea
- >50%: arthralgia, vomiting
- >25%: abdominal pain, dry cough, eye pain, diarrhea, photophobia, neck pain

<https://www.cdc.gov/relapsing-fever/clinicians/index.html>


The Illness

- Fever up to 106.7°F “chill phase” (10-30 mins)
 - May become delirious, agitated, tachycardic and tachypneic
- Followed by the “flush phase”
 - Drenching sweats and a rapid decrease in body temperature.
 - Transiently hypotensive.
- Patients who are not treated will experience several episodes of fever before illness resolves.

<https://www.cdc.gov/relapsing-fever/clinicians/index.html>

Recovery


- Treatment:
 - Doxycycline – 2x daily, 7 days
- Immune control



<https://www.cdc.gov/relapsing-fever/clinicians/index.html>

Antigenic shift

- Genomic organization unique
- Allows shift of antigen on cell surface
 - “Hide and seek”
- Eventually WBCs win



<https://www.cdc.gov/relapsing-fever/clinicians/index.html>


Testing

- Peripheral blood smear
- IgG serology
- Real-time PCR

Blood smear


- Peripheral blood smear, performed like blood parasite screen or CBC
 - Giemsa, Wright, or Wright-Giemsa
- Good for initial diagnosis, low sensitivity
- Turn-around-time = hours
- Requires skilled readers, patience, and experience

Blood Smear in the Literature



Badger MS. Wilderness Env Med J 2008. 19(4): 280-286.


In Reality




In Reality



In Reality (with Photoshop assistance)



In Reality (with Photoshop assistance)



Serology

- Retrospective diagnosis or support of recent diagnosis
- Four-fold rise in IgG titer
- Cross-reactivity with Lyme
 - Lyme false-positives
- Not widely available
 - Imugen (Oxford)
 - Quest Diagnostics


PCR

- High sensitivity
- High specificity (if well designed)
- No FDA cleared assays
- Challenges
 - Detect all relevant species to N. America vs Eurasia/Africa or both
 - Do NOT detect Lyme *Borrelia* species
 - Find samples or organism to validate with

Remember this patient?

Patient sample tested by in-house design, sequenced positive for *B. hermsii*.

- Patient stayed at cabin in southeastern California mountains



PCR Development at ARUP

- Designed to detect *B. hermsii*, *B. parkeri*, *B. turicatae*, and *B. miyamotoi* (identical sequence) from blood
 - Can also detect: *B. crocidurae*, *B. duttoni*, *B. hispanica*, *B. recurrentis*, and *B. microti*
 - TBRF *Borrelia* spp. from Europe, Asia, Africa
 - Differ by one base pair, slightly less sensitive – can differentiate this group by melt curve analysis
 - Will not detect *B. persica* (Middle Eastern endemic)
- No cross-reactivity with Lyme *Borrelia* spp or 68 other pathogens
 - Including *Anaplasma*, *Babesia*, and multiple *Plasmodium* species

PCR Testing in Prime Time

- Available commercially at major reference labs:
 - ARUP Laboratories
 - Mayo Medical Laboratories
 - Quest Diagnostics

TBRF In Summary

- TBRF causes a textbook illness reminiscent of malaria or *Babesia* but with distinct patterning of fevers
- Caused by many species of *Borrelia*
 - Vectored by several different ticks in different regions
- Detected by multiple mechanisms, commercially available
- Likely underreported due to insensitivity of blood smear
 - PCR is significantly more sensitive

A Fatal Headache

- 5 yo boy admitted w/ right-sided headache, drowsy, fever 101°F
 - Abnormal brain EEG, normal CSF count
- 2 days later fever 103°F, lymphocytic predominance in CSF
 - Became unconscious and unresponsive to stimuli
- 4 days after admission, completely comatose and encephalitic
 - Patient ceased breathing in the afternoon
- 6 days later passed away

...the year was 1958...

...the town was Powassan, Ontario

...no tick bite was ever reported

McLean DM, Donahue W. Can Med Assoc J 1959; 80: 708–711.

Deer Tick Virus or Powassan virus, lineage II

Deer Tick Virus (DTV)

- DTV is one genotype of Powassan virus
 - Powassan virus lineage I = POWV = *Ixodes cookei*
 - Powassan virus lineage II = DTV = *Ixodes scapularis*
- Flavivirus closely related to tick-borne encephalitis group of viruses in Europe & Asia
- Discovered in 1958 in brain tissue
 - Fatal pediatric encephalitis in Powassan, Ontario


McLean DM, Donahue W. Can Med Assoc J 1959; 80: 708–711.

Case Distribution

- Likely underreported, but possibly increasing
 - 1958 – 1998 = 27 cases reported
 - 2003 – 2016 = 85 cases reported
- Cases found everywhere *Ixodes* exist
 - Colorado as rare exception
 - Incidentally found in *Dermacentor andersoni*


Hermance and Thangamani. 2017 Vector Borne and Zoonotic Diseases. 17(7), 453-462.

Case Distribution – ArboNET 2017




<https://diseasemaps.usgs.gov/mapviewer/>

Case Distribution – ArboNET 2018




<https://diseasemaps.usgs.gov/mapviewer/>

Case Distribution – ArboNET 2019



<https://diseasemaps.usgs.gov/mapviewer/>

Symptoms



Hermance and Thangamani. 2017 Vector Borne and Zoonotic Diseases. 17(7), 453-462.

Clinical Diagnosis

Symptomatic/retrospective


- Serology – IgM of serum or CSF

Post mortem

- Culture of virus
- PCR detection of viral RNA
- Histopathology with immunohistochemistry

None available through commercial labs – CDC or state PHL only

IgM Serology



Hernance and Thangamani. 2017 Vector Borne and Zoonotic Diseases. 17(7), 453-462.

DTV In Summary

- Emerging, life threatening tick-borne viral illness
 - Vectored by *Ixodes* tick
- Likely underreported infection
 - Very limited testing capacities
 - Should only be investigated after more common causes ruled out
- Cases with encephalitis are likely to be identified (or maybe not)

Questions?

Three realistic red ticks are positioned around the word 'Questions?'. One tick is on the left side of the 'Q', one is on top of the 'i' in 'Questions', and one is on the right side of the 's'.